Myomo (MYO) Stock Price, News & Analysis

Company Overview

Myomo, Inc. is a medical technology company that develops, manufactures and markets wearable robotic devices designed to help people with neuromuscular disorders and upper-limb weakness regain movement and perform activities of daily living. The company’s products combine powered actuators, sensors and user-controlled interfaces in lightweight orthotic systems.

Myomo’s principal product is the MyoPro, a powered upper-limb orthosis intended for individuals whose arm and hand function has been impaired by conditions such as stroke, brachial plexus injury, multiple sclerosis, spinal cord injury or other neurological disorders. The device is customized and fitted for each user and is designed to support voluntary movement rather than replace it.

Founded in 2004, Myomo is headquartered in Boston, Massachusetts. It markets its products in the United States and internationally through a combination of direct sales, clinical referral networks and distribution partners. The company works with rehabilitation professionals, physicians and orthotists to evaluate patients, fit devices and support ongoing use.

Key Stats

• Today's Range: $1.47 to $1.58
• 50-Day Range: $0.90 to $1.86
• 52-Week Range: $0.61 to $1.89
• Volume: 352,704 shs
• Average Volume: 440,351 shs
• Market Capitalization: $62.19 million
• P/E Ratio: N/A
• Dividend Yield: N/A
• Price Target: $10.00
• Consensus Rating: Buy

Myomo Stock Analysis - MarketRank™

Myomo scored higher than 61% of companies evaluated by MarketBeat. Scores are calculated by averaging available category scores, with extra weight given to analysis and valuation.

Analyst's Opinion

• Score: 3.5 / 5
• Analyst Rating: Buy

Consensus Rating

Myomo has received a consensus rating of Buy. The company's average rating score is 3.00, and is based on no strong buy ratings, 2 buy ratings, no hold ratings, and no sell ratings.

Upside Potential

Myomo has a consensus price target of $10.00, representing about 536.9% upside from its current price of $1.57.

Amount of Analyst Coverage

Myomo has received no research coverage in the past 90 days.

Earnings and Valuation

• Score: 0.6 / 5
• Proj. Earnings Growth: Growing

Earnings Growth

Earnings for Myomo are expected to grow in the coming year, from ($0.32) to ($0.25) per share.

Price to Earnings Ratio vs. the Market

The P/E ratio of Myomo is -4.62, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.

Price to Earnings Ratio vs. Sector

The P/E ratio of Myomo is -4.62, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.

Price to Book Value per Share Ratio

Myomo has a P/B Ratio of 5.23. P/B Ratios above 3 indicate that a company could be overvalued with respect to its assets and liabilities.

Short Interest

• Score: 3.0 / 5
• Short Interest Level: Healthy

Percentage of Shares Shorted

3.42% of the float of Myomo has been sold short.

Short Interest Ratio / Days to Cover

Myomo has a short interest ratio ("days to cover") of 1.6, which is generally considered an acceptable ratio of short interest to trading volume.

Change versus previous month

Short interest in Myomo has recently increased by 5.96%, indicating that investor sentiment is decreasing significantly.

Dividend

• Score: 0.0 / 5
• Dividend Strength: N/A

Dividend Yield

Myomo does not currently pay a dividend.

Dividend Growth

Myomo does not have a long track record of dividend growth.

News and Social Media

• Score: 3.0 / 5
• News Sentiment: N/A

News Sentiment

Myomo has a news sentiment score of 0.88. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This is a higher news sentiment than the 0.51 average news sentiment score of Healthcare companies.

Search Interest

Only 2 people have searched for MYO on MarketBeat in the last 30 days. This is a decrease of -78% compared to the previous 30 days.

MarketBeat Follows

4 people have added Myomo to their MarketBeat watchlist in the last 30 days.

Company Ownership

• Score: 1.7 / 5
• Insider Trading: Selling Shares

Insider Buying vs. Insider Selling

In the past three months, Myomo insiders have sold more of their company's stock than they have bought. Specifically, they have bought $0.00 in company stock and sold $70,662.00 in company stock.

Percentage Held by Insiders

12.14% of the stock of Myomo is held by insiders. A high percentage of insider ownership can be a sign of company health.

Percentage Held by Institutions

44.99% of the stock of Myomo is held by institutions. High institutional ownership can be a signal of strong market trust in this company.

Company Calendar

• Last Earnings: 8/05/2026
• Today: 9/21/2026
• Next Earnings (Estimated): 11/09/2026
• Fiscal Year End: 12/31/2026

Industry, Sector and Symbol

• Stock Exchange: NYSEAMERICAN
• Sector: Healthcare
• Industry: Healthcare Equipment & Supplies
• Sub-Industry: Healthcare Equipment
• Current Symbol: NYSEAMERICAN:MYO
• CIK: 1369290
• Web: myomo.com
• Phone: (617) 996-9058
• Fax: N/A
• Employees: 195
• Year Founded: N/A

Price Target and Rating

• Average Price Target for Myomo: $10.00
• High Price Target: $10.00
• Low Price Target: $10.00
• Potential Upside/Downside: +536.9%
• Consensus Rating: Buy
• Rating Score (0-4): 3.00
• Research Coverage: 2 Analysts

Profitability

• EPS (Trailing Twelve Months): ($0.23)
• Trailing P/E Ratio: N/A
• Forward P/E Ratio: N/A
• P/E Growth: N/A
• Net Income: -$15.57 million
• Net Margins: -33.53%
• Pretax Margin: -32.52%
• Return on Equity: -138.85%
• Return on Assets: -39.18%

Debt

• Debt-to-Equity Ratio: 1.98
• Current Ratio: 2.31
• Quick Ratio: 2.01

Sales & Book Value

• Annual Sales: $40.93 million
• Price / Sales: 1.52
• Cash Flow: N/A
• Price / Cash Flow: N/A
• Book Value: $0.30 per share
• Price / Book: 5.23

Miscellaneous

• Outstanding Shares: 39,610,000
• Free Float: 34,800,000
• Market Cap: $62.19 million
• Optionable: Not Optionable
• Beta: 1.50